News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Altor BioScience Corporation and the Melanoma Research Alliance to Co-Support Clinical Studies of Altor’s Novel IL-15 Superagonist for Metastatic Melanoma


4/30/2012 10:25:23 AM

MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation (Altor), a leading developer of immunotherapeutics for curative treatment of metastatic malignancies, announced today that it will jointly sponsor with the Melanoma Research Alliance (MRA) a clinical study of Altor’s novel IL-15 superagonist, ALT-803, against metastatic melanoma at the University of Washington. MRA is a public charity focused on funding the most promising melanoma research worldwide.

Read at BioSpace.com


comments powered by Disqus
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES